{
  "id": "5e52c9266d0a27794100004e",
  "type": "yesno",
  "question": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?",
  "ideal_answer": "Yes,  there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17327465",
    "http://www.ncbi.nlm.nih.gov/pubmed/28944315"
  ],
  "snippets": [
    {
      "text": " Based on our review of the data, there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines. We also found no evidence that short-term treatment with RMAhRLs produce \"dioxin-like toxicity\"",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, recent discoveries of new AhR ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on our review of the data, there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on our review of the data , there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However , recent discoveries of new AhR ligands with potential therapeutic applications have been reported , inviting reconsideration of this policy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on our review of the data, there is little evidence to support the indiscriminate exclusion of AhR activators/Cyp1a1 inducers from early drug developmental pipelines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, recent discoveries of new AhR ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17327465",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}